DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Blocking antibody
Blocking antibody
(Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated with Enteritis and Hypophysitis James C
BAVENCIO (Avelumab) Injection, for Intravenous Use Function
Reference ID: 4734770 Dexamethasone Is Not Recommended Outside of Controlled Clinical Trials
Immune-Checkpoint Inhibitors from Cancer to COVID-19
S41467-019-11980-6.Pdf
Inhibiting Phagocytosis with Cd47: from the Effects of Red Cell Rigidity and Shape to Display on Lentivirus - Implications for Aging and Gene Therapy
A Reappraisal of CTLA-4 Checkpoint Blockade in Cancer Immunotherapy
Non-Small Cell Lung Cancer
CTLA-4 Blockade Reverses the Foxp3+ T-Regulatory-Cell Suppression of Anti-Tuberculosis T-Cell Effector Responses
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and in Vivo Toxicology in Non-Human Primates
Ipilimumab – Fact Sheet
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T Cell Dependent
The Role of T Cell Trafficking in CTLA-4 Blockade-Induced Gut
Therapeutic Antitumor Immunity by Checkpoint Blockade Is Enhanced by Ibrutinib, an Inhibitor of Both BTK And
PD-1 Inhibitors
Developing a Rational Tumor Vaccinetherapy for Renal Cell
Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
CCR5 Blockade Inflames Antitumor Immunity in BAP1-Mutant Clear Cell
Top View
Antitumor Efficacy of Combined CTLA4/PD-1 Blockade Without Intestinal
Lifting the Innate Immune Barriers to Antitumor Immunity
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T Cell Dependent
Harnessing the Immune System to Combat Cancer W
Atezolizumab for the First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
Functional Antibodies Focus: Recombinant Antibodies
Transmission-Blocking Strategies
Targeting Interference of CTLA-4 Co-Inhibition to Tumour-Specific T-Cells to Enhance Activity and Reduce Toxicity
Autoimmune Antibodies Correlate with Immune Checkpoint Therapy-Induced Toxicities
CTLA-4 Blockade Bioassay Instructions for Use of Products JA3001 and JA3005
Cancer Immunotherapy: the Beginning of the End of Cancer? Sofia Farkona1,2, Eleftherios P
YERVOY (Ipilimumab)
A Dormant TIL Phenotype Defines Non-Small Cell Lung Carcinomas
Immune Check Point Inhibitors-Induced Hypophysitis
Hypophysitis from Immune Checkpoint Inhibitors: Challenges in Diagnosis and Management
Bavencio-Pi.Pdf
Harnessing Herd Immunity for Malaria Elimination
Ipilimumab-Induced Thrombotic Thrombocytopenic Purpura (TTP) Jeanelle King1, Javier De La Cruz2 and Jose Lutzky1*
A Combined PD-1/C5a Blockade Synergistically Protects Against Lung Cancer Growth and Metastasis